Positive News SentimentPositive NewsNASDAQ:GTHX G1 Therapeutics (GTHX) Stock Forecast, Price & News $1.44 +0.09 (+6.67%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.34▼$1.4450-Day Range$1.22▼$2.4052-Week Range$1.17▼$13.85Volume445,210 shsAverage Volume411,934 shsMarket Capitalization$74.52 millionP/E RatioN/ADividend YieldN/APrice Target$11.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside719.4% Upside$11.80 Price TargetShort InterestHealthy5.60% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$10,866 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector327th out of 972 stocksPharmaceutical Preparations Industry134th out of 445 stocks 3.4 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.80, G1 Therapeutics has a forecasted upside of 719.4% from its current price of $1.44.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.60% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently decreased by 1.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 2.7 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 51 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,866.00 in company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.04% of the stock of G1 Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About G1 Therapeutics (NASDAQ:GTHX) StockG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 5, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 4, 2023 | msn.comWedbush Reiterates G1 Therapeutics (GTHX) Outperform RecommendationAugust 3, 2023 | msn.comNeedham Maintains G1 Therapeutics (GTHX) Buy RecommendationAugust 2, 2023 | finance.yahoo.comG1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational HighlightsAugust 1, 2023 | markets.businessinsider.comG1 Therapeutics earnings: here's what Wall Street expectsJuly 31, 2023 | finance.yahoo.comG1 Therapeutics to Participate in Two August Investor ConferencesOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.July 31, 2023 | finance.yahoo.comNew Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)July 27, 2023 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutionsJuly 26, 2023 | finance.yahoo.comG1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023June 26, 2023 | markets.businessinsider.comWhere G1 Therapeutics Stands With AnalystsJune 26, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for G1 Therapeutics (GTHX)June 5, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on G1 Therapeutics (GTHX)June 4, 2023 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Path To ProfitabilityJune 4, 2023 | finance.yahoo.comTrilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and EfficacyMay 22, 2023 | finance.yahoo.comG1 Therapeutics Announces Appointment of Monica Thomas as General CounselMay 16, 2023 | finance.yahoo.comNew Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung CancerMay 10, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for G1 Therapeutics (GTHX)May 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)May 10, 2023 | msn.comG1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patientsMay 10, 2023 | finance.yahoo.comNew Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)May 8, 2023 | finance.yahoo.comAnalysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)May 5, 2023 | finance.yahoo.comG1 Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 4, 2023 | msn.comRaymond James Maintains G1 Therapeutics (GTHX) Outperform RecommendationMay 4, 2023 | msn.comHC Wainwright & Co. Reiterates G1 Therapeutics (GTHX) Buy RecommendationSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Company Calendar Last Earnings8/02/2023Today10/01/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees170Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.80 High Stock Price Forecast$19.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+719.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,560,000.00 Net Margins-87.26% Pretax Margin-83.89% Return on Equity-143.26% Return on Assets-46.84% Debt Debt-to-Equity Ratio0.89 Current Ratio4.14 Quick Ratio3.68 Sales & Book Value Annual Sales$51.30 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book0.90Miscellaneous Outstanding Shares51,750,000Free Float47,487,000Market Cap$74.52 million OptionableOptionable Beta1.87 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 58)CEO, Pres & Director Comp: $1.06MDr. Mark A. Velleca M.D. (Age 59)Ph.D., Sr. Advisor & Director Comp: $245kMr. Mark Avagliano (Age 47)Chief Bus. Officer Comp: $628.54kMr. John W. Umstead V (Age 38)Chief Financial Officer Mr. Terry L. Murdock (Age 63)Chief Operating Officer Mr. William C. Roberts (Age 54)VP of Investor Relations & Corp. Communications Mr. Alexander D. Smith M.S.VP of Technical OperationsMs. Monica R. ThomasGen. Counsel & Chief Compliance OfficerDr. Jay C. Strum Ph.D. (Age 59)Chief Scientific Officer Mr. Evan Hicks M.B.A.VP of MarketingMore ExecutivesKey CompetitorsKinnate BiopharmaNASDAQ:KNTESpero TherapeuticsNASDAQ:SPROShattuck LabsNASDAQ:STTKCleneNASDAQ:CLNNTiziana Life SciencesNASDAQ:TLSAView All CompetitorsInsiders & InstitutionsWoodline Partners LPSold 150,437 shares on 8/15/2023Ownership: 0.291%XTX Topco LtdSold 184,444 shares on 8/15/2023Ownership: 0.212%Goldman Sachs Group Inc.Bought 34,826 shares on 8/15/2023Ownership: 0.186%Y Intercept Hong Kong LtdBought 22,855 shares on 8/15/2023Ownership: 0.044%Citadel Advisors LLCBought 5,400 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GTHX Stock - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 1-year price objectives for G1 Therapeutics' shares. Their GTHX share price forecasts range from $5.00 to $19.00. On average, they anticipate the company's stock price to reach $11.80 in the next twelve months. This suggests a possible upside of 719.4% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2023? G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has decreased by 73.5% and is now trading at $1.44. View the best growth stocks for 2023 here. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.31. The company earned $42.39 million during the quarter, compared to the consensus estimate of $28.34 million. G1 Therapeutics had a negative net margin of 87.26% and a negative trailing twelve-month return on equity of 143.26%. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $1.44. How much money does G1 Therapeutics make? G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $74.52 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How many employees does G1 Therapeutics have? The company employs 170 workers across the globe. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830. This page (NASDAQ:GTHX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.